Merck announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. “At Merck, we continue...
Indian pharmaceutical companies must fulfill new manufacturing requirements this year, according to a Union Health Ministry announcement, but tiny companies have requested a delay, citing their financial load. Under the revised Schedule...
Sensorion announces that the research partnership framework agreement signed in 2019 with the Institut Pasteur (Paris, France), which granted Sensorion an option for exclusive licenses to develop and market gene therapy drug candidates derived...
AbbVie and Umoja Biopharma (Umoja), a biotechnology startup in early clinical stages, signed two exclusive option and licensing agreements to develop numerous in-situ produced CAR-T cell treatment candidates in oncology using Umoja's patented...
The UK Medicines and Healthcare Regulatory Agency (MHRA) has granted Clinical Trial Authorization (CTA) for PharmaKure to begin a multi-ascending dose phase 2a study to assess the safety and tolerability of PK051, intended for the treatment of...
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical firm, announced the launch of the Lasmiditan tablet, which is used to treat migraines. The Drug Controller General of India (DCGI) and the United States Food and Drug...
IASO Biotherapeutics (IASO Bio), a biopharmaceutical company that discovers, develops, manufactures, and markets innovative cell therapies and antibody products, announced a new set of collaborations with Umoja Biopharma, Inc. (Umoja)...
BridGene Biosciences, Inc., a leader in small molecule drug development targeting conventional "hard-to-drug" targets, announced a strategic collaboration and license arrangement with Galapagos NV. Under the collaboration, BridGene will use its...
The US Food and Drug Administration (FDA) has approved OBI Pharma's investigational new drug (IND) application for OBI-992, allowing the company to move forward with a phase 1/2 study of its innovative antibody-drug conjugate (ADC) cancer therapy...
According to two persons familiar with the situation, Quadria Capital, an Asia-focused private equity fund, is in advanced talks to acquire a significant minority position in India's largest dialysis chain, NephroPlus, for 2,000 crore...
, CDSCO.jpg)
